In vitro and in vivo models have demonstrated a decrease in PXR and FXR signaling in IBD, with a concomitant improvement in intestinal inflammatory lesions with PXR and FXR agonism9,10,20,36. This evidence concerns the gene NR1H4 and inflammatory bowel disease.